Product Images Divalproex Sodium

Divalproex Sodium is a delayed-release tablet containing 250mg. The package quantity is 30, and it is RX only. The manufacturer is Sun Pharma located in Cranbury, NJ, and it should be stored at 20-25°C (83-77°F) with excursions of 15-30°C (53-86°F). It comes in a package with an NDC# of 70518-3431-01 and an expiration date. Directions for use are available in the package insert. Packaged by RemedyRepack Inc., Indiana. It is important to keep this and all medication out of the reach of children.*

This is a prescription medication called Divalproex Sodium in tablet form, manufactured by Sun Pharma. Each bottle contains 100 tablets with a strength of 250 mg. The National Drug Code (NDC) for this medication is 70518-3431-02, and the Lot# and expiration date are indicated on the bottle packaging. The medication is a delayed-release formulation, and the package insert should be consulted for dosing instructions. The medication should be stored at controlled room temperature, and kept out of reach of children. The medication was repackaged by RemedyRepack Inc. in Indiana, PA.*

This is a prescription medication called Divalproex Sodium in 250mg tablets. The source NDC is 62756-0797-13, and it was manufactured by Sun Pharma in Cranbury, NJ. It has a delayed-release and a specific LOT number and expiration date. The medication should be kept out of the reach of children and stored at a temperature between 20-25°C (58-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP guidelines. There are no specific instructions for use listed other than to see the package insert. It was repackaged by RemedyRepack Inc. in Indiana, PA.*

This text appears to be a chart or graph presenting data related to CPS rate reduction and patient improvement, with percentages ranging from -100% to 100%. The chart includes two categories, DVPX and Placebo, and different levels of improvement and worsening. Without additional context or a clear image of the chart, it is difficult to provide a more specific description of the data being presented.*

The text is a chart showing mean 4-week migraine rates for Placebo and DVPX in Study 1 and Study 2.*